drugset / Trial / NCT03586843

A Study of JNJ-64565111 After Single Subcutaneous Administration at Different Injection Sites in Otherwise Healthy Overweight/Obese Adult Participants and a Study of JNJ-6456511 in Otherwise Healthy Obese Adult Participants After Multiple Dose

NCT03586843

Phase 1 Completed 52 enrolled Janssen Research & Development, LLC
RandomizedCrossoverOpen-labelOther

Summary

The purpose of this study is to compare the relative bioavailability of JNJ-64565111 between subcutaneous (SC) administrations in the upper arm versus the abdomen, and between SC administrations in the thigh versus the abdomen in otherwise healthy overweight/obese participants (Part A) and to assess the gastrointestinal tolerability of JNJ-64565111 following a dose titration in otherwise healthy obese participants at 6 weeks (Part B).

Timeline

Start
2018-06-29
Primary completion
2019-03-17
Completion
2019-03-17

Drugs

EvaluationDrugModalityDoseRoute
Subject JNJ-64565111 Unknown Subcutaneous

Indications